

University of Groningen

Author's Reply to Correspondence: "Effect of Tolvaptan Treatment on Acid-Base Homeostasis in ADPKD Patients"

Heida, Judith E; Gansevoort, Ron T; Meijer, Esther

Published in:
Kidney International Reports

DOI:
[10.1016/j.ekir.2021.04.014](https://doi.org/10.1016/j.ekir.2021.04.014)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Heida, J. E., Gansevoort, R. T., & Meijer, E. (2021). Author's Reply to Correspondence: "Effect of Tolvaptan Treatment on Acid-Base Homeostasis in ADPKD Patients". *Kidney International Reports*, 6(6), 1749-1750. <https://doi.org/10.1016/j.ekir.2021.04.014>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Effect of Tolvaptan Treatment on Acid–Base Homeostasis in ADPKD Patients



To the Editor: We read with great interest the recent report of Heida *et al.*¹ on the impact of tolvaptan on acid–base status in autosomal dominant polycystic kidney disease (ADPKD) patients. The authors hypothesized that V2 receptor antagonism may induce a state of metabolic alkalosis by activation of V1 receptors through increased circulating vasopressin, which in turn would stimulate renal net acid excretion (NAE). The authors found no changes in plasma bicarbonate after tolvaptan administration and therefore concluded that tolvaptan does not affect renal NAE.

Recent studies^{2,3} indicate, however, that urinary citrate is superior to plasma bicarbonate for the detection of subtle acid–base alterations. We previously observed that ADPKD patients treated with tolvaptan exhibit a significant reduction in renal NAE, with an increase in urinary citrate.⁴ These changes were associated with increased net gastrointestinal alkali absorption (NGIA; a marker of alkali intake) but unaltered urinary sulfate (a marker of acid intake), suggesting that lower NAE may be due to higher alkali intake or gut alkali absorption in patients taking tolvaptan. Thus, our data suggest that tolvaptan treatment is associated with changes in renal NAE and hence acid–base homeostasis in ADPKD patients. The underlying mechanisms, however, remain to be elucidated.

1. Heida JE, Gansevoort RT, Meijer E. Acid-base homeostasis during vasopressin V2 receptor antagonist treatment in autosomal dominant polycystic kidney disease patients. *Kidney Int Rep.* 2021;6:839–841.
2. Gianella FG, Prado VE, Poindexter JR, et al. Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease. *Kidney Int.* 2021;99:208–217.
3. Goraya N, Simoni J, Sager LN, et al. Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. *Kidney Int.* 2019;95:1190–1196.
4. Bargagli M, Dhayat NA, Anderegg M, et al. Urinary lithogenic risk profile in ADPKD patients treated with tolvaptan. *Clin J Am Soc Nephrol.* 2020;15:1007–1014.

Matteo Bargagli¹, Pietro Manuel Ferraro¹, Nasser Dhayat², Manuel Anderegg² and Daniel Fuster²

¹U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy and ²Division of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Correspondence: Matteo Bargagli, U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Roma, Italia. E-mail: matteo.bargagli@unicatt.it

Received 23 March 2021; accepted 5 April 2021; published online 28 April 2021

Kidney Int Rep (2021) 6, 1749; <https://doi.org/10.1016/j.ekir.2021.04.012>

© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid–Base Homeostasis in ADPKD Patients”



We thank Matteo Bargagli and his colleagues for their interest in our study and suggestion to investigate the urinary citrate excretion as a more sensitive measure of change in acid–base regulation than plasma bicarbonate. In their study, they describe urinary citrate excretion to be higher and net renal acid excretion to be lower in ADPKD patients using tolvaptan compared to ADPKD patients without tolvaptan.¹ Direct comparison of results is hampered by the fact that both studies have not measured the entire acid–base profile. We did not measure urinary citrate and net renal acid excretion, which would have been valuable additions, and Bargagli and colleagues did not measure plasma pH, bicarbonate, and pCO₂. However, results of these 2 studies are consistent in their rejection of our primary hypothesis. Tolvaptan does not seem to induce an increase in bicarbonate reabsorption in the investigated patients.

1. Bargagli M, Dhayat NA, Anderegg M, et al. Urinary lithogenic risk profile in ADPKD patients treated with tolvaptan. *Clin J Am Soc Nephrol.* 2020;15:1007–1014.

Judith E. Heida, Ron T. Gansevoort and
Esther Meijer

Department of Nephrology, University Medical Center Groningen,
University of Groningen, Groningen, The Netherlands

Correspondence: Esther Meijer, nephrologist, University Medical
Center Groningen, PO 30.001, 9700 RB Groningen, The Netherlands.
E-mail: esther.meijer@umcg.nl

**Received 12 April 2021; accepted 13 April 2021; published online
27 April 2021**

Kidney Int Rep (2021) **6**, 1749–1750; [https://doi.org/10.1016/
j.ekir.2021.04.014](https://doi.org/10.1016/j.ekir.2021.04.014)

© 2021 International Society of Nephrology. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).